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Increased DNA Methylation of ABCB1, CYP2D6, and OPRM1 Genes in
Newborn Infants of Methadone-Maintained Opioid-Dependent Mothers
Poppy McLaughlin, PhD1, Helen Mactier, MBChB, MD, FRCPCH2, Cheryl Gillis, MBChB2, Tamas Hickish, MA, MD, FRCP3,
Anton Parker, BSc3, Wei-Jun Liang, PhD1, and M. David Osselton, PhD, FRCS1
Objective To investigate whether in utero opioid exposure, which has been linked to adverse neurodevelopmental
and social outcomes, is associated with altered DNA methylation of opioid-related genes at birth.
Study design Observational cohort study of 21 healthy methadone-maintained opioid-dependent mother–infant
dyads consecutively delivered at >36 weeks of gestation, and 2 comparator groups: smoking, “deprived”
opioid-naïve mother-infant dyads (n = 17) and nonsmoking, “affluent” opioid-naïve mother-infant dyads (n = 15).
DNA methylation of ABCB1, CYP2D6, and OPRM1 genes for mothers and babies was determined from buccal
swabs. Plasma methadone concentrations were additionally measured for methadone-maintained opioid-
dependent mothers.
Results DNA methylation for ABCB1 and CYP2D6 was similar in opioid-naïve infants compared with their mothers,
but was less for OPRM1 (3 ± 1.6% vs 8 ± 1%, P < .0005). Opioid-exposed newborns had similar DNA methylation
to their mothers for all genes studied and greater methylation of ABCB1 (18 ± 4.8% vs 3 ± 0.5%), CYP2D6 (92 ± 1.2%
vs 89 ± 2.4%), and OPRM1 (8 ± 0.3% vs 3 ± 1.6%) compared with opioid-naïve newborns (P < .0005 for all 3 genes).
Infant DNA methylation was not related to birth weight, length of hospital stay, maternal smoking, dose or plasma
concentration of methadone at delivery, or postcode of residence.
Conclusions In utero exposure to opioids is associated with increased methylation of opioid-related genes in
the newborn infant. It is not clear whether these findings are due to opioid exposure per se or other associated
lifestyle factors. (J Pediatr 2017;■■:■■-■■).
M ethadone maintenance is the international standard of care for pregnant opioid dependent women.
1 Despite the
advantages of methadone in stabilizing maternal lifestyle, there are problems associated with its use. Infants of
methadone-maintained opioid-dependent (MMOD) mothers have shorter gestation periods, lower birth weights,
smaller head circumferences, and are at risk of developing neonatal abstinence syndrome (NAS).2,3 Visuocortical function is
impaired at birth,4 and the adverse effects of in utero opioid exposure continue into early childhood, adversely impacting
upon visual development as well as cognitive, psychomotor, and behavioral performance.5-7 It is not clear to what extent
factors such as poverty and coexistent illicit drug and alcohol misuse contribute to adverse outcomes for infants of opioid-
dependent mothers. Social and psychological problems may persist to adulthood, and there is some evidence of intergenerational
substance misuse, particularly between substance misusing mothers and their daughters, although the mechanisms of this are
poorly understood.8,9
Mechanisms by which opioids may influence fetal development include inhibition of neuronal proliferation and differen-
tiation with increased cell death, alterations in endocrine function, and modifications to myelin sheath formations,5,10 and it is
feasible that fetal and later childhood outcomes of opioid-exposed pregnancies are influenced by in utero changes to DNA
methylation.11
Increased DNA methylation on the µ-opioid receptor gene (OPRM1) in sperm and white blood cells in adult subjects has
been attributed to opioid misuse,12-14 and has also been described in relation to the development of NAS in methadone-
exposed newborns.15 To date no studies have reported DNA methylation of opioid-related genes in infants of MMOD mothers
compared with opioid-naïve infants.
The aims of this study were to compare differences in DNA methylation on se-
lected opioid-related genes (ABCB1, CYP2D6, and OPRM1) between MMOD
mothers and their newborn infants and opioid-naive mothers and their newborn
infants, and to examine whether DNA methylation in the newborn is associated
with in utero growth, development of NAS, or length of hospital stay.We also sought
CpG Cytosine-phosphate-guanine dinucleotide
DEPCAT Deprivation score
MMOD Methadone-maintained opioid-dependent
NAS Neonatal abstinence syndrome
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to investigate whether maternal cigarette smoking or postcode
of resident (as a proxy for socioeconomic deprivation) influ-
ence DNA methylation in the newborn.
Methods
All MMOD mothers delivering after 36 completed weeks of
gestation at Princess Royal Maternity in Glasgow were eli-
gible to participate in the study. Potential subjects were
identified in the postnatal wards, soon after delivery. These
mothers had been managed within an established multidis-
ciplinary service for women with social problems including
substance misuse; antenatal care included ongoing metha-
done maintenance provided in collaboration with social
work and addiction services and tailored to symptoms. Suf-
ficient methadone was prescribed to eliminate physical
withdrawals, with the aim of reducing toward the lowest
acceptable dose of methadone in the weeks before delivery.
Exclusion criteria included unwell babies and those born
before 36 completed weeks of gestation.
Within 24-72 hours of delivery and following informed pa-
rental consent, a buccal swab (Catch-All; Cambio Ltd, Cam-
bridge, United Kingdom) was obtained from the baby and a
venous blood sample obtained from the mother for estima-
tion of trough plasmamethadone concentration. The latter was
drawn shortly before administration of the once daily pre-
scribed dose of methadone. Demographic data including ma-
ternal age, prescribed methadone dose at delivery, smoking
status, and postcode of residence were extracted from case
records. Deprivation score (DEPCAT) was calculated from
postcode using Carstairs index.16 Use of other drugs (illicit or
prescribed) was determined from case records and from in-
dividual discussion with mothers as well as from urine samples
immediately postnatally, when available. Routine antenatal urine
toxicology was not hospital policy and, thus, was not in-
cluded in this study.
Infant gestation, birth weight, and length of hospital stay
were also recorded from case records. All babies were nursed
in the postnatal ward with their mothers and NAS was
managed according to protocol; scoring used a local version
of the Lipsitz scale.17 Infants scoring 5 or more on 2 consecu-
tive occasions and/or with poor feeding or ongoing weight
loss after 5 days were commenced on oral morphine at a
dose of 60 µg/kg 6 times daily. Treatment was escalated to
80 µg/kg/dose if the baby remained symptomatic otherwise
morphine was weaned daily by 10 µg/kg/dose. If NAS symp-
toms were not controlled by oral morphine, phenobarbital
was given in addition. Regardless of treatment, all infants
remained with their mother in hospital for a minimum of 5
days. Length of stay for treated babies was determined by
success of weaning of morphine; for treatment periods greater
than 10-12 days, the mother was discharged from hospital
and baby admitted to the neonatal unit. Following weaning
of oral morphine, phenobarbital treatment could be contin-
ued as an outpatient. Breast feeding was encouraged for all
babies. The research team was not involved in any decision
to treat an infant.
To control for the effects of cigarette smoking and poverty
on DNA methylation, 2 groups of nonopioid dependent
mother-infant dyads were recruited from the postnatal wards
of the same maternity hospital, based on maternal smoking
(yes or no) and postcode of residence. Cigarette smoking
mothers from DEPCAT scores 4-7 comprised a “deprived”
group and nonsmoking mother-infant dyads from more af-
fluent areas of Glasgow (DEPCAT 1-3) an“affluent”group.Oral
swabs were obtained from opioid-naïve mothers and infants
within 24-48 hours of delivery and maternal age, infant birth
weight, and gestation recorded. Infant buccal swabs were col-
lected before commencement of treatment for NAS.All mothers
and babies were of Caucasian origin.
Limited funding allowed for investigation of 50 mother-
infant dyads in this pilot study; we aimed, therefore, to recruit
20 MMOD and 15 each deprived and affluent nonopioid-
exposed dyads. The study was approved by West of Scotland
Research Ethics Committee 5, and all mothers gave informed,
written consent.
Methylation Analysis
DNA extracted from buccal swabs underwent bisulfite con-
version using the EZ DNA Methylation-Gold kit protocol
(Zymo Research, Frieburg, Germany) and was amplified by a
Veriti Thermal Cycler (Life Technologies, Carlsbad, Califor-
nia). Percentage methylation was quantified using the Q24
Pyrosequencer (Qiagen, Hilden, Germany). Details of the
primers used are listed in Table I (available at www.jpeds.com).
The ABCB1 gene primers amplify the −356 bp to −265 bp
region relative to the ATG start codon that contains 11 cytosine-
phosphate-guanine dinucleotide (CpG) sites. Three CpG sites
of CYP2D6 were investigated. The 2 regions of OPRM1 am-
plified (promoter (−30 bp to −7 bp) and exon 1 (+12 bp to
+27 bp)) contain 8 CpG sites of interest.
Methadone Analysis
Methadone was isolated from 1 mL of plasma at the Toxicol-
ogy Unit, Imperial College, London by liquid-liquid extrac-
tion, using clomipramine-D3 as the internal standard.
Quantification was undertaken using a Hewlett Packard 6890
gas chromatograph linked to a 5973 mass spectrometer.
Statistical Analyses
Statistical analyses were conducted using SPSS v 23 (SPSS Inc,
Chicago, Illinois). Maternal age, gestation, birth weight, and
gene methylation differences between the opioid-exposed and
naïve mother, and infant populations were determined using
1-way ANOVA, as were the differences between gene meth-
ylation and requirement for NAS treatment. The data were in-
terrogated for outliers by visually inspecting box plots, and
normality was assessed using the Shapiro-Wilk test. If either
of these tests were violated, the data were transformed. If trans-
formation of the data did not produce normal distribution,
Welch and Games-Howell post-hoc tests were undertaken. For
normally distributed data with no outliers, Tukey post-hoc tests
were carried out.
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Results
Twenty-one of 22 consecutively delivered MMODmothers ap-
proached agreed to participate in the study, and samples were
obtained from all 21 mother-infant dyads. In addition, 17 de-
prived and 15 affluent (opioid-naïve) mother-infant dyads were
recruited. Affluent and MMOD mothers were of similar age
(median 32 years); deprived mothers were younger (28 years,
P = .02) (Table II). Gestation ranged from 36+1 to 42+0 (mean
38+6) weeks and did not differ between opioid-exposed and
opioid-naïve infants born in either affluent or deprived
postcodes. Birth weight did not differ between affluent and de-
prived controls but was lower in the MMOD group than com-
bined controls (2815 ± 352.5 g vs 3386 ± 533.7 g, P < .0005).
Median hospital stay for infants of MMOD mothers was 11
days (range 5-42 days); opioid-naïve infants were discharged
home with their mothers within 24-72 hours after birth, de-
pending on mode of delivery.
MMODmothers had been prescribed a mean daily metha-
done dose of 59 ± 27.6 mg at delivery. Plasma samples were
obtained from 18 of 21 MMOD mothers; median metha-
done plasma concentration was 245 (range 60-720 µg/L). In
addition to prescribed maintenance methadone, all MMOD
mothers had smoked cigarettes, and amajority admitted to con-
sumption of other drugs, including heroin (smoked or in-
jected), prescription and/or illicit benzodiazepines, and cannabis.
Eleven of 21 infants born to MMOD mothers required treat-
ment for NAS; 2 of these treated babies additionally required
phenobarbital.
There was little variation in methylation between CpG sites
for each of the genes studies, and so averaged results were used.
ABCB1
ABCB1 methylation was assessed for 20 opioid-naïve infants,
9 opioid-naïve mothers, 19 opioid-exposed infants, and 18
MMODmothers.ABCB1methylation was the same in opioid-
naïve mothers and infants, and in opioid-exposed mothers and
their infants, but was significantly higher in the opioid-
exposedmother-infant dyads, compared with opioid-naïve sub-
jects (3 ± 0.5% in opioid naïve newborns; 3 ± 0.4% in opioid
naïve mothers; 18 ± 4.8% in opioid exposed newborns;
16 ± 8.3% in MMOD mothers (Welch F[3, 28.174] = 56.031,
P < .0005) (Figure).
CYP2D6
CYP2D6 methylation was assessed for 32 opioid-naïve infants
and their mothers and for 18MMODmothers and their infants.
There were no differences between opioid-naïve or opioid-
exposed infants and their mothers (Figure). CYP2D6 meth-
ylation was marginally but significantly higher in MMOD
mothers (92 ± 1.7%) and their infants (92 ± 1.2%) com-
pared with opioid-naïve mothers (89 ± 4.2%) and their infants
(89 ± 2.4%) (Welch F [3, 48083] = 14.755, P < .0005).
OPRM1
OPRM1 methylation was assessed for 30 opioid-naïve infants,
29 opioid-naïve mothers, 20 opioid-exposed infants, and 19
MMODmothers.OPRM1methylation was significantly lower
in opioid-naïve infants (3 ± 1.6%) compared with in opioid-
naïve mothers (8 ± 2.0%), opioid-exposed infants (8 ± 0.3%),
Table II. Mother and infant demographics
MMOD (n = 21) Deprived (n = 17) Affluent (n = 15) P
Maternal age (y, mean ± SD) 32 ± 4 28 ± 6 33 ± 4 .01
Maternal smoking (n, %) 21 (100) 16 (94) 0 (0) —
Gestation (wk, mean ± SD) 39 ± 1 40 ± 1 39 ± 2 .15
Birth weight (g, mean ± SD) 2815 ± 353 3364 ± 549 3413 ± 533 <.01
Figure. ABCB1, CYP2D6, and OPRM1 gene DNA methyla-
tion in MMOD mothers and their newborns compared with
opioid-naïve mothers and newborns. Opioid-exposed new-
borns had higher % methylation than opioid naive newborns
on all genes investigated. Similar methylation was observed
on the OPRM1 gene between MMOD and opioid naïve mothers,
however, methylation was higher on ABCB1 and CYP2D6 in
MMOD mothers. White filled column = opioid-naïve new-
borns; solid grey column = opioid-exposed newborns; check-
ered white filled column = opioid-naive mothers; checkered gray
filled column = MMOD mothers.
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and in MMODmothers (9 ± 0.1%). (Games-Howell post hoc
analysis; −4.61 (95% CI −5.90 to −3.33; P < .0005), 4.99 (95%
CI −5.81 to −4.17; P < .0005), and −5.20 (95% CI −6.03 to
−4.36; P < .0005), respectively. (Figure).
There was no relationship between infant DNA methyla-
tion of any of the genes studied and either birth weight, length
of hospital stay, maternal dose, or plasma concentration of
methadone. DNA methylation was not different between
opioid-exposed newborns who did or did not require treat-
ment for NAS (Table III).
Discussion
We explored DNAmethylation on ABCB1 and CYP2D6 genes
in methadone exposed newborns, and also compared DNA
methylation between opioid-exposed and opioid-naïve new-
borns.We found DNAmethylation of all 3 opioid-related genes
in newborn infants of MMOD mothers to be similar to that
of their mothers, and higher than that of opioid-naïve new-
borns. Increased methylation onOPRM1 is consistent with the
study of Wachman et al15 who analyzed a larger population
(n = 86) of infants exposed to maternal opioids, 65% of whom
required pharmacologic treatment for NAS. Our failure to
confirm an association between increased methylation of the
OPRM1 promoter and severity of NAS may well be a type II
error, reflective of our smaller study numbers.
Opioid misuse is associated with numerous lifestyle factors
deleterious to health.We did not have accurate toxicology data
to confirm additional substance use, but from previous studies
in a very similar population, we assume that this was common
and most likely to be illicit opioids and benzodiazepines.2 Pre-
natal exposures to antidepressants, antiepileptic drugs, alcohol,
antibiotics, and tobacco have all been associated with altered
neonatal DNAmethylation.19-24We did not see an effect of ciga-
rette smoking upon DNA methylation in opioid-naïve new-
borns, but study numbers were small. Socioeconomic
deprivationmay also have contributed to increased DNAmeth-
ylation in opioid-exposed mother-infant dyads.25 We did not
find any differences between opioid-naïve “deprived” and “af-
fluent” dyads, but we acknowledge that numbers were small,
and that postcode of residence is a poor proxy for social de-
privation. Besides small patient numbers, a limitation of the
present study is that the nutritional intake of mothers was not
obtained. It is, therefore, not possible to conclude if the in-
creased DNA methylation of ABCB1, CYP2D6, and OPRM1
genes observed in opioid-exposed newborns was due to ma-
ternal prescribed substitute methadone, ongoing illicit drug
use, or other lifestyle factors associated with drug misuse.
Disparity in gene methylation between opioid-exposed and
opioid-naïve infants could have originated during any stage
of fetal development. Fertilization and early embryogenesis is
a particularly sensitive period of epigenetic reprograming when
paternal and maternal genomes are actively and passively
demethylated to facilitate the conversion from somatic to
germline epigenotype that enables cell differentiation.26 A plau-
sible mechanism by which methadone could increase DNA
methylation is through G-protein-coupled receptor-mediated
increase of DNA methyltransferase activity,14 mediated by ac-
tivation of mitogen-activated protein kinase-dependent
pathways.27,28
Higher maternal DNAmethylation on ABCB1 andOPRM1
observed in opioid-naïve dyads would be predicted as a result
of age associated epigenetic alterations of CpG rich regions29
whereas the lack of difference between opioid-naïve mother
and infant CYP2D6 gene methylation could be a tissue spe-
cific phenomenon. CYP2D6 gene expression is not necessary
in buccal DNA and may not reflect methylation of brain DNA.
The association of hypermethylation with methadone treat-
ment suggests interaction between opioids and mechanisms
of classical epigenetics.30 Global DNA methylation analysis18
would have addressed whether our observations reflect a global
increase in DNAmethylation rather than a specific effect upon
a few genes but was beyond the scope and purpose of this par-
ticular study.
DNAmethylation of ABCB1,CYP2D6, andOPRM1 opioid-
related genes is increased in newborn infants of MMOD
mothers, but the mechanisms of this are not clear. The effect
of this phenomenon should be explored in relation to the in-
fant’s behavior and susceptibility to disease and drug use later
in life.
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Table III. Relationship between gene methylation and development of NAS requiring treatment (opioid-exposed new-
borns only)
ABCB1 (%) P CYP2D6 (%) P OPRM1 (%) P
Treated NAS
n = 10
Range 12.9-23.1 0.3 91.0-93.9 0.9 8.0-9.0 1.0
Mean ± SD 18.9 ± 2.8 92.0 ± 1.1 8.5 ± 0.3
No NAS
n = 11
Range 4.8-23.3 88.9-93.5 8.2-8.8
Mean ± SD 16.6 ± 6.4 92.1 ± 9.4 8.5 ± 0.2
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Table I. Primers for polymerase chain reaction and pyrosequencing
Genes (region amplified) PCR primers* (no. of cycles, annealing temperature) Pyrosequencing primers
ABCB1 (promoter) F:AAAACAAAATTAAAAATCTAACAAC
R:Bio-TTAGATTTAGGAGTTTTTGGAGTAG
(50, 57°C)
Seq 1: TGGTATTGGATTATGTTGTT
Seq 2: TGGGTGGGAGGAAGT
CYP2D6 (exon 1) F:Bio-TGGAGTAGGAAGTAGGGGTAAGAAT
R:AACACAAAAAACCAAACAAAACAC
(35, 58.5°C)
AAACACTCTCAACACACC
OPRM1 (promoter) F:GGATTGGTTTTTGTAAGAAATAGTA
R:Bio-CTAAAAACAACCCTACTATCCATAATA (35, 50°C)
AGTTTAGGTGTTTTTGGTTA
OPRM1 (exon 1) F:Bio-GGATTGGTTTTTGTAAGAAATAGTA
R:CTAAAAACAACCCTACTATCCATAATAC (35, 58°C)
CCAAAACATCAATACAATTA
Bio, biotin labeled; PCR, polymerase chain reaction.
*ABCB1 primers designed by Dejeux et al18 were used; primers for CYP2D6 and OPRM1 were designed in-house.
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